DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACALABRUTINIB

« Back to Dashboard

All Clinical Trials for Acalabrutinib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02029443 ↗	ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia	Active, not recruiting	Acerta Pharma BV	Phase 1/Phase 2	2014-01-01	This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
NCT02157324 ↗	Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia	Active, not recruiting	Acerta Pharma BV	Phase 1	2014-08-01	This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
NCT02180711 ↗	An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma	Active, not recruiting	Acerta Pharma, LLC	Phase 1	2014-07-01	To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL)
NCT02180711 ↗	An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma	Active, not recruiting	Acerta Pharma BV	Phase 1	2014-07-01	To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL)
NCT02211014 ↗	An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma	Active, not recruiting	Acerta Pharma, LLC	Phase 1	2015-02-01	To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
NCT02211014 ↗	An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma	Active, not recruiting	Acerta Pharma BV	Phase 1	2015-02-01	To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
NCT02213926 ↗	An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma	Active, not recruiting	Acerta Pharma BV	Phase 2	2014-09-01	The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).

Clinical Trial Conditions for Acalabrutinib

Condition Name

Condition Name for Acalabrutinib
Intervention	Trials
Chronic Lymphocytic Leukemia	21
Mantle Cell Lymphoma	15
Small Lymphocytic Lymphoma	7
Diffuse Large B Cell Lymphoma	5

Condition MeSH

Condition MeSH for Acalabrutinib
Intervention	Trials
Lymphoma	46
Leukemia, Lymphocytic, Chronic, B-Cell	30
Leukemia, Lymphoid	28
Leukemia	24

Clinical Trial Locations for Acalabrutinib

Trials by Country

Trials by Country for Acalabrutinib
Location	Trials
United States	138
United Kingdom	7
Poland	6
Canada	5
Italy	4

Trials by US State

Trials by US State for Acalabrutinib
Location	Trials
Texas	14
Ohio	12
California	11
Washington	11
New York	11

Clinical Trial Progress for Acalabrutinib

Clinical Trial Phase

Clinical Trial Phase for Acalabrutinib
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	12
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Acalabrutinib
Clinical Trial Phase	Trials
Not yet recruiting	64
Recruiting	20
Active, not recruiting	10

Clinical Trial Sponsors for Acalabrutinib

Sponsor Name

Sponsor Name for Acalabrutinib
Sponsor	Trials
AstraZeneca	34
Acerta Pharma BV	33
National Cancer Institute (NCI)	16

Sponsor Type

Sponsor Type for Acalabrutinib
Sponsor	Trials
Industry	81
Other	73
NIH	17